Brian Gallagher, Phd
Board of Directors
Pharmaceutical
Navitor Pharmaceuticals
United States of America
Biography
Brian M. Gallagher, Jr., PhD is a Partner at SR One Ltd. He established the SR One Boston office in 2010, and is focused on building innovative therapeutic and life science companies. In addition to Navitor, Dr. Gallagher currently represents SR One on the boards of Aileron Therapeutics, CalciMedica, Constellation Pharmaceuticals, Nimbus Discovery, RaNA Therapeutics, and River Vision. He previously led the firm’s investments in Dicerna Pharmaceuticals (NASDAQ: DRNA) and SpringLeaf Therapeutics. Dr. Gallagher has more than 15 years of investing, business development, operational and R&D experience in both biotechnology and large pharma companies. He joined SR One from Sirtris Pharmaceuticals, where he was responsible for corporate development and operations, as well as post-merger integration following the $720M acquisition of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Dr. Gallagher was with Alantos Pharmaceuticals, where he played key roles in R&D and business development activities and led many aspects of the post-merger integration following the $300M acquisition of Alantos by Amgen in 2007. Brian M. Gallagher, Jr., PhD is a Partner at SR One Ltd. He established the SR One Boston office in 2010, and is focused on building innovative therapeutic and life science companies. In addition to Navitor, Dr. Gallagher currently represents SR One on the boards of Aileron Therapeutics, CalciMedica, Constellation Pharmaceuticals, Nimbus Discovery, RaNA Therapeutics, and River Vision. He previously led the firm’s investments in Dicerna Pharmaceuticals (NASDAQ: DRNA) and SpringLeaf Therapeutics. Dr. Gallagher has more than 15 years of investing, business development, operational and R&D experience in both biotechnology and large pharma companies. He joined SR One from Sirtris Pharmaceuticals, where he was responsible for corporate development and operations, as well as post-merger integration following the $720M acquisition of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Dr. Gallagher was with Alantos Pharmaceuticals, where he played key roles in R&D and business development activities and led many aspects of the post-merger integration following the $300M acquisition of Alantos by Amgen in 2007.
Research Interest
Business Development
